NCT04156178 - CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 1, 2018

Primary Completion Date

September 30, 2020

Study Completion Date

September 30, 2020

Conditions

B Cell LymphomaB Cell Leukemia

Interventions

BIOLOGICAL

CD20-CD19 cCAR T cells

CD20-CD19 cCAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy

Trial Locations (2)

Unknown

RECRUITING

Chengdu Military General Hospital, Chengdu

RECRUITING

Peking University Shenzhen Hospital, Shanghai